Company intelligence / Profile preview

JSSK Neurocare

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

JSSK Neurocare's lead product, the Catfish stent retriever, has demonstrated safety and non-inferior efficacy compared to the Solitaire stent retriever for the treatment of acute ischemic stroke caused by large vessel occlusion (ELVO). Clinical trial results published in 2023 (NCT03820882) showed high rates of successful recanalization and similar clinical outcomes to the industry standard.

Therapeutic areas: Neurology
Modalities: Medical Device
Industry: Surgical Medical Devices

Partnerships

Beijing Tiantan HospitalCapital Medical University

Beyond the preview

Go deeper on JSSK Neurocare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JSSK Neurocare.

Explore the full profile